🟢 Moderna is trading 4.1% up today ahead of Q2 earnings and RSV vaccine traction

Moderna is trading 4.1% up at $60.27 as investors position ahead of its Q2 2026 earnings report on July 31 and monitor early traction for its RSV vaccine, mRESVIA.

• Market focus is centered on the upcoming financial results and the commercial rollout of the company's newly approved respiratory syncytial virus (RSV) vaccine.
• The move aligns with a broader tech-led market rebound and firmer Nasdaq futures, indicating supportive sentiment for growth-oriented stocks alongside company-specific catalysts.